Wells Fargo’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$45.7M Sell
77,138
-13,802
-15% -$6.87M 0.01% 1019
2025
Q4
$44.3M Buy
90,940
+12,819
+16% +$5.97M 0.01% 1005
2025
Q3
$32.7M Sell
78,121
-29,605
-27% -$9.96M 0.01% 1159
2025
Q2
$31M Buy
107,726
+33,649
+45% +$10.1M 0.01% 1117
2025
Q1
$22.8M Sell
74,077
-2,193
-3% -$752K 0.01% 1241
2024
Q4
$26.9M Buy
76,270
+55
+0.1% +$20.2K 0.01% 1156
2024
Q3
$27.3M Sell
76,215
-8,932
-10% -$3.02M 0.01% 1106
2024
Q2
$27.1M Buy
85,147
+21,684
+34% +$5.74M 0.01% 1064
2024
Q1
$14.6M Buy
63,463
+16,239
+34% +$3.66M ﹤0.01% 1453
2023
Q4
$10.4M Sell
47,224
-7,281
-13% -$1.68M ﹤0.01% 1679
2023
Q3
$12.3M Buy
54,505
+886
+2% +$204K ﹤0.01% 1415
2023
Q2
$11.8M Buy
53,619
+73
+0.1% +$16.2K ﹤0.01% 1482
2023
Q1
$12M Buy
53,546
+4,410
+9% +$1.09M ﹤0.01% 1464
2022
Q4
$13.7M Sell
49,136
-24,494
-33% -$6.18M ﹤0.01% 1345
2022
Q3
$15.4M Buy
73,630
+8,263
+13% +$1.85M 0.01% 1237
2022
Q2
$15.4M Sell
65,367
-34,480
-35% -$7.01M ﹤0.01% 1290
2022
Q1
$17.9M Buy
99,847
+17,915
+22% +$3.41M ﹤0.01% 1379
2021
Q4
$17.7M Sell
81,932
-350,171
-81% -$68.7M ﹤0.01% 1425
2021
Q3
$79.8M Buy
432,103
+156,299
+57% +$30.8M 0.02% 778
2021
Q2
$49.5M Sell
275,804
-68,786
-20% -$13.1M 0.01% 1067
2021
Q1
$57.6M Buy
344,590
+39,864
+13% +$6.65M 0.01% 966
2020
Q4
$46.3M Sell
304,726
-31,047
-9% -$4.07M 0.01% 1036
2020
Q3
$33.9M Sell
335,773
-91,656
-21% -$10.1M 0.01% 1070
2020
Q2
$51.7M Buy
427,429
+374,621
+709% +$42.2M 0.02% 831
2020
Q1
$5.01M Buy
52,808
+2,817
+6% +$268K ﹤0.01% 2220
2019
Q4
$4.4M Sell
49,991
-18,550
-27% -$1.63M ﹤0.01% 2677
2019
Q3
$5.47M Sell
68,541
-80,678
-54% -$6.5M ﹤0.01% 2469
2019
Q2
$11.6M Sell
149,219
-195,739
-57% -$18.3M ﹤0.01% 1850
2019
Q1
$40.5M Sell
344,958
-50,459
-13% -$5.88M 0.01% 1015
2018
Q4
$43.1M Sell
395,417
-76,132
-16% -$8.83M 0.01% 900
2018
Q3
$60.3M Sell
471,549
-2,892
-0.6% -$358K 0.02% 829
2018
Q2
$53.7M Buy
474,441
+19,395
+4% +$2.13M 0.02% 879
2018
Q1
$51.1M Sell
455,046
-289,266
-39% -$36.7M 0.02% 883
2017
Q4
$110M Buy
744,312
+14,593
+2% +$1.86M 0.03% 530
2017
Q3
$85.5M Sell
729,719
-915
-0.1% -$117K 0.03% 615
2017
Q2
$94.8M Buy
730,634
+431,210
+144% +$53.8M 0.03% 567
2017
Q1
$40.5M Sell
299,424
-118,982
-28% -$18M 0.01% 959
2016
Q4
$60M Buy
418,406
+396,064
+1,773% +$50.6M 0.02% 730
2016
Q3
$2.64M Sell
22,342
-5,778
-21% -$694K ﹤0.01% 2742
2016
Q2
$2.98M Buy
28,120
+5,321
+23% +$594K ﹤0.01% 2691
2016
Q1
$2.54M Sell
22,799
-7,676
-25% -$971K ﹤0.01% 2754
2015
Q4
$4.77M Buy
30,475
+9,778
+47% +$1.42M ﹤0.01% 2359
2015
Q3
$2.72M Sell
20,697
-57,645
-74% -$9.25M ﹤0.01% 2777
2015
Q2
$13.6M Sell
78,342
-82,039
-51% -$14.8M 0.01% 1663
2015
Q1
$27.7M Sell
160,381
-19,197
-11% -$2.93M 0.01% 1124
2014
Q4
$23.3M Sell
179,578
-10,366
-5% -$1.34M 0.01% 1188
2014
Q3
$24.4M Sell
189,944
-228,485
-55% -$23.6M 0.01% 1136
2014
Q2
$37M Sell
418,429
-50,188
-11% -$4.83M 0.02% 933
2014
Q1
$44.1M Sell
468,617
-30,729
-6% -$3.14M 0.02% 821
2013
Q4
$56.5M Sell
499,346
-62,412
-11% -$5.63M 0.02% 691
2013
Q3
$44.3M Sell
561,758
-41,964
-7% -$3.07M 0.02% 746
2013
Q2
$39.7M Buy
+603,722
New +$38.9M 0.02% 740

Other funds holding UTHR

Wells Fargo's UTHR Position: Q1 2026 in Review

Wells Fargo reduced its United Therapeutics (UTHR) stake by 15% in Q1 2026, selling an estimated $6.87M and leaving 77,138 shares worth $45.7M. The position accounts for 0.01% of the portfolio, ranked #1019.

Wells Fargo first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $110M in Q4 2017. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Wells Fargo held 77,138 shares of United Therapeutics worth $45.7M as of Q1 2026.
  • Wells Fargo sold 13,802 United Therapeutics shares in Q1 2026, an estimated $6.87M.
  • United Therapeutics made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #1019 holding.
  • Wells Fargo first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's United Therapeutics position peaked at $110M in Q4 2017.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.